 |
|
|
| |
Safety and Efficacy of Long-Term Tenofovir Alafenamide Treatment in Patients Aged 60 Years and Older With Chronic Hepatitis B: Experience From Two Phase 3 Clinical Trials
|
| |
| |
EASL 2026 May 26-30 Barcelona
Scott K Fung1, Maria Buti2,3, Jinlin Hou4, Kosh Agarwal5, Qin Ning6, Grace Lai-Hung Wong7, Young-Suk Lim8, Wan-Long Chuang9, Frida Abramov10, Hongyuan Wang10, Irina Botros10, Leland J Yee10, Cihan Yurdaydin11, Hiroshi Yatsuhashi12, Patrick Marcellin13,
Edward J Gane14, Henry LY Chan15
1Department of Medicine, University of Toronto, Toronto, ON, Canada; 2Hospital Universitario Vall d'Hebron, Barcelona, Spain; 3Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD) del Instituto Carlos III, Madrid, Spain; 4Department of Infectious Diseases, State Key Laboratory of Organ Failure Research, Nanfang Hospital, Southern Medical University, Guangzhou, China; 5Institute of Liver Studies, King's College Hospital NHS Foundation Trust, London, UK; 6Tongji Hospital, Tongji Medical College, Wuhan, China; 7Medical Data Analytics Centre, Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Shatin, Hong Kong; 8Asan Medical Centre, University of Ulsan College of Medicine, Seoul, South Korea; 9Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan; 10Gilead Sciences, Inc., Foster City, CA, USA; 11Department of Gastroenterology and Hepatology, Koç University Medical School, Istanbul, Turkey; 12Clinical Research Center, National Hospital Organization Nagasaki Medical Center, Nagasaki, Japan; 13Association for the Promotion of Hepatologic Care and University of Paris, Paris, France; 14University of Auckland, Auckland, New Zealand; 15Faculty of Medicine, The Chinese University of Hong Kong, Shatin, Hong Kong
|
| |
|
|
|
|
|
